Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02452970
Title RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy (EPIC)
Acronym EPIC
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors EpicentRx, Inc.
Indications
Therapies
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center Baltimore Maryland 21287 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field